We’re excited to share a major milestone for BioReact: the company has closed an oversubscribed $1.07M pre-seed round led by New Stack Ventures, marking an important step forward in the company’s mission to modernize bioprocess development with AI.
Bioprocessing sits at the foundation of modern biotech, yet the workflows that support it remain fragmented, manual, and difficult to scale. BioReact was built to change that.
Where Bioprocessing Meets AI
BioReact’s platform automatically aligns online and offline data from virtually every bioreactor and offline data source, bringing everything into a single, collaborative environment. Instead of juggling spreadsheets, siloed systems, and disconnected datasets, teams can visualize experiments, track performance, and collaborate seamlessly—all in one place.
At BioReact, AI isn’t a buzzword—it’s core to the product. The platform is trained on 12M+ data points across widely used organisms, including CHO, yeast, Pichia, HEK293, E. coli, and more, enabling faster iteration cycles and more confident decision-making for bioprocess scientists.
Why We Led the Round
At New Stack Ventures, we look for teams building category-defining infrastructure in markets that have been underserved by modern software. BioReact stood out for its deep technical foundation, clear understanding of the bioprocess scientist’s workflow, and ambition to become the system of record for bioprocess data.
We believe BioReact has the potential to meaningfully accelerate development timelines and unlock new levels of efficiency across the biotech ecosystem.
What’s Next
With this funding, BioReact will continue investing in product development, expanding platform capabilities, and accelerating commercialization with forward-thinking biotech teams.
We’re thrilled to partner with Mitchell Castetter and the entire BioReact team as they build the next generation of software for bioprocess scientists.
Learn more at https://www.bioreact.co/